Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 11:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 267 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Systemic Sclerosis (Scleroderma) Clear all
Completed Not applicable Interventional

Rehabilitation for Arm Coordination and Hand Movement in Systemic Sclerosis

NCT03482219
View directory record Official record
Conditions
Systemic Sclerosis, SSc
Interventions
Occupational therapy, Home app intervention
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Oct 15, 2026, 11:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Optical Elastography of Systemic Sclerosis Skin

NCT02835196
View directory record Official record
Conditions
Scleroderma
Interventions
Optical Elastography, Visual Assessment
Device · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 15, 2026, 11:33 AM EDT
Completed Not applicable Interventional Results available

A Study to Evaluate the Efficacy of an Oral Medication in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis (Scleroderma).

NCT00725361
View directory record Official record
Conditions
n Ulcer, Scleroderma, Systemic
Interventions
Ambrisentan
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 15, 2026, 11:33 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

NCT06655155
View directory record Official record
Conditions
Systemic Sclerosis (SSc)
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Combination Product · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Plantation, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 15, 2026, 11:33 AM EDT
Withdrawn Phase 2 Interventional

A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)

NCT02588625
View directory record Official record
Conditions
Scleroderma
Interventions
BMS-986020, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
19
States / cities
Scottsdale, Arizona • Los Angeles, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2016 · Synced Oct 15, 2026, 11:33 AM EDT
Completed Phase 2 Interventional

Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis

NCT00016458
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
anti-thymocyte globulin, cyclophosphamide
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
3
States / cities
Denver, Colorado • Durham, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 3, 2008 · Synced Oct 15, 2026, 11:33 AM EDT
Recruiting Not applicable Interventional

Systemic Sclerosis DIet for GastrointESTinal Symptoms

NCT07402226
View directory record Official record
Conditions
Systemic Sclerosis (SSc)
Interventions
Diet 1: Restriction of fermentable carbohydrates, Diet 2: Elimination of foods harmful to gut barrier and microbiome, Diet 3: Regular meal patterns, soluble fiber, and portion control
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 15, 2026, 11:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pain Outcomes Following Intralesional Corticosteroid Injections

NCT03630198
View directory record Official record
Conditions
Keloid, Alopecia Areata, Acne, Hypertrophic Scar, Epidermal Inclusion Cyst, Frontal Fibrosing Alopecia, Lichen Plano-Pilaris, Keratoacanthoma, Plaque Psoriasis, Lichen Simplex Chronicus, Prurigo Nodularis, Nummular Eczema, Granuloma Annulare, Morphea, Lichen Planus
Interventions
Corticosteroid with lidocaine, Corticosteroid with normal saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Oct 15, 2026, 11:33 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

NCT05869955
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Rheumatoid Arthritis
Interventions
CC-97540, Fludarabine, Cyclophosphamide, Tocilizumab
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
25
States / cities
Aurora, Colorado • Denver, Colorado • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 15, 2026, 11:33 AM EDT
Not yet recruiting Early Phase 1 Interventional

Hyaluronidase for Sclerodactyly in Systemic Sclerosis Trial

NCT07697274
View directory record Official record
Conditions
Systemic Sclerosis, Sclerodactyly
Interventions
Hyaluronidase (Hylenex)
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 15, 2026, 11:33 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis

NCT03817424
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, Dermatomyositis
Interventions
VIB7734, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
19
States / cities
Anniston, Alabama • Birmingham, Alabama • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 15, 2026, 11:33 AM EDT
Terminated Phase 2 Interventional Results available

Abituzumab in SSc-ILD

NCT02745145
View directory record Official record
Conditions
Systemic Sclerosis-associated Interstitial Lung Disease
Interventions
Abituzumab 1500 mg, Abituzumab 500 mg, Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
18
States / cities
Los Angeles, California • Farmington, Connecticut • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Oct 15, 2026, 11:33 AM EDT
Completed Phase 3 Interventional

Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon

NCT00266669
View directory record Official record
Conditions
Raynaud's Disease
Interventions
Topical organogel with nitroglycerin
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
17
States / cities
Stanford, California • Denver, Colorado • Farmington, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2007 · Synced Oct 15, 2026, 11:33 AM EDT
Active, not recruiting Phase 2 Interventional

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

NCT02682511
View directory record Official record
Conditions
Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic, Skin Diseases, Connective Tissue Diseases, Pathologic Processes, Autoimmune Diseases
Interventions
Oral Ifetroban, Oral Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
10
States / cities
Tucson, Arizona • Los Angeles, California • Weston, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 15, 2026, 11:33 AM EDT
Not listed Phase 3 Interventional

A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon

NCT00577304
View directory record Official record
Conditions
Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Other Autoimmune Disease
Interventions
Nitroglycerin, Topical AmphiMatrix
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
15 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Stanford, California • Denver, Colorado • Farmington, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2010 · Synced Oct 15, 2026, 11:33 AM EDT
Completed No phase listed Observational

Calcinosis in a Single-Center Scleroderma Population

NCT02062125
View directory record Official record
Conditions
Scleroderma, Calcinosis
Interventions
Not listed
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 85 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 15, 2026, 11:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Scleroderma Registry

NCT00074568
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 70 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Oct 15, 2026, 11:33 AM EDT
Withdrawn Phase 2Phase 3 Interventional

CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH

NCT03726398
View directory record Official record
Conditions
Interstitial Lung Disease, Scleroderma, Pulmonary Hypertension
Interventions
Opsumit 10 Mg Tablet
Drug
Lead sponsor
Franz Rischard, DO
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 15, 2026, 11:33 AM EDT
Terminated Phase 2 Interventional Results available

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

NCT05000216
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
Interventions
Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 15, 2026, 11:33 AM EDT
Completed Phase 2 Interventional Results available

Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma

NCT02370784
View directory record Official record
Conditions
Scleroderma
Interventions
atorvastatin, Placebo
Drug
Lead sponsor
Robyn T. Domsic, MD, MPH
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Oct 15, 2026, 11:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Finger Hardness Measure in Scleroderma

NCT01111786
View directory record Official record
Conditions
Scleroderma
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 15, 2026, 11:33 AM EDT
Completed Phase 2 Interventional Results available

Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)

NCT01933334
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Pirfenidone
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
18
States / cities
Scottsdale, Arizona • Los Angeles, California • Redwood City, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Oct 15, 2026, 11:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Angiogenic/Angiostatic Mediators in Patients With Systemic Sclerosis

NCT00668473
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 15, 2026, 11:33 AM EDT
Recruiting Phase 2 Interventional

A Study of Microbiome Transplantation for the Treatment of Constipation and/or Significant Bloating in Patients With Systemic Sclerosis

NCT06827977
View directory record Official record
Conditions
Constipation, Bloating
Interventions
PRIM-DJ2727, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 15, 2026, 11:33 AM EDT